UBS analyst Danielle Antalffy assumed coverage of Abbott with a Buy rating and $117 price target as part of a sector note on U.S. Medical Supplies and Devices. UBS believes Abbott’s ability to sustain above-market Medical Devices growth and top-tier high-single-digit total company sales growth is underappreciated, and sees Abbott’s recent and upcoming product launches as offering a plethora of shots on goal to sustain its recent positive momentum within Medical Devices, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott initiated with a Buy at UBS
- TD Cowen medical devices analyst to hold analyst/industry conference call
- DexCom pullback on Abbott news a buying opportunity, says Jefferies
- Wells downgrades Edwards Lifesciences with Medtronic gaining share
- BofA says buy DexCom on weakness after Abbott’s Libre gets pump integration